Reduced mania and depression in juvenile bipolar disorder associated with long-chain omega-3 polyunsaturated fatty acid supplementation.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8804070 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5640 (Electronic) Linking ISSN: 09543007 NLM ISO Abbreviation: Eur J Clin Nutr Subsets: MEDLINE

Publication: <2003->: London : Nature Publishing Group
Original Publication: London : J. Libbey, c1988-

Dietary Supplements*; Antidepressive Agents/*therapeutic use ; Antimanic Agents/*therapeutic use ; Bipolar Disorder/*drug therapy ; Docosahexaenoic Acids/*therapeutic use ; Eicosapentaenoic Acid/*therapeutic use; Adolescent ; Adolescent Behavior/drug effects ; Bipolar Disorder/blood ; Child ; Child Behavior/drug effects ; Docosahexaenoic Acids/blood ; Docosahexaenoic Acids/pharmacology ; Drug Therapy, Combination ; Eicosapentaenoic Acid/blood ; Eicosapentaenoic Acid/pharmacology ; Erythrocytes/drug effects ; Female ; Fish Oils/therapeutic use ; Humans ; Male

Long-chain omega-3 polyunsaturated fatty acid (LCn-3PUFA) supplementation may improve symptoms of depression in children and bipolar disorder (BD) in adults. No studies have examined the effectiveness of LCn-3PUFA supplementation in the treatment of mania and depression in juvenile BD (JBD) when given as an adjunct to standard pharmacological treatment. Eighteen children and adolescents with JBD received supplements containing 360 mg per day eicosapentaenoic acid (EPA) and 1560 mg per day docosahexaenoic acid (DHA) for 6 weeks in an open-label study. Intake and fasting red blood cell (RBC) LCn-3PUFA, mania, depression and global function were assessed before and after supplementation. RBC EPA and DHA were significantly higher following supplementation. Clinician ratings of mania and depression were significantly lower and global functioning significantly higher after supplementation. Parent ratings of internalizing and externalizing behaviours were also significantly lower following supplementation. A larger randomized controlled trial appears warranted in this participant population.

0 (Antidepressive Agents)
0 (Antimanic Agents)
0 (Fish Oils)
25167-62-8 (Docosahexaenoic Acids)
AAN7QOV9EA (Eicosapentaenoic Acid)

Date Created: 20090122 Date Completed: 20091015 Latest Revision: 20131121

20231215

10.1038/ejcn.2008.81

19156158